When a coronavirus vaccine might be ready
Co-founder of Inovio Pharmaceuticals Dr. David Weiner details the current status of a possible coronavirus vaccine, including efficacy trials which he says should start this summer.
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
Americans are paying a fearsome price for the government’s strict lockdowns of American life and commerce, and now comes evidence that targeted lockdowns aimed at protecting those who are most vulnerable to the coronavirus would be better for public health and the economy.
That conclusion comes in a new working paper from the National Bureau of Economic Research by MIT economists Daron Acemoglu, Victor Chernozhukov, Iván Werning and Michael Whinston. The authors compared relative risks of infection, hospitalization and death for the young, the middle-aged and those over age 65. They then compared strict lockdowns that treat all age groups the same with a more targeted strategy that protects the old.
CLICK HERE TO SIGN UP FOR OUR OPINION NEWSLETTER
“Interestingly, we find that semi-targeted policies that simply apply a strict lockdown on the oldest group can achieve the majority of the gains from fully-targeted policies,” the authors write. “For example, a semi-targeted policy that involves the lockdown of those above 65 until a vaccine arrives can release the young and middle-aged groups back into the economy much more quickly, and still achieve a much lower fatality rate in the population (just above 1% of the population instead of 1.83% with the optimal uniform policy).”
CLICK HERE TO GET THE FOX NEWS APP
Interesting is right. The universal lockdowns of March and April have been aimed specifically at preventing hospitals from being overrun with Covid-19 patients and thus reducing the death rate. But the paper says a targeted lockdown aimed at seniors combined with other policies like social distancing will reduce the death rate by more.
CLICK HERE TO CONTINUE READING THIS EDITORIAL IN THE WALL STREET JOURNAL
Get the recap of top opinion commentary and original content throughout the week.